How should a 60-year-old woman with neuropathic pain on pregabalin and duloxetine, who has grade 2 fatty liver disease and presents with dizziness and decreased appetite, be managed?

Management of Dizziness and Decreased Appetite in a 60-Year-Old Woman on Pregabalin and Duloxetine with Grade 2 Fatty Liver

The dizziness is most likely caused by pregabalin, and you should reduce the pregabalin dose immediately while maintaining duloxetine, as both medications are known to cause these symptoms but pregabalin is the more common culprit, especially in older adults. The decreased appetite is likely from duloxetine, but this is typically transient and less concerning than the dizziness which poses fall risk.

Immediate Assessment and Action

Identify the Culprit Medication

Dizziness is a dose-dependent adverse effect of both pregabalin and duloxetine, but pregabalin causes dizziness far more frequently 1, 2, 3. In controlled trials, dizziness occurred in older adults (≥65 years) more frequently with pregabalin than in younger patients 3. The FDA label specifically warns that pregabalin causes dose-dependent dizziness and sedation 3.

Decreased appetite is a recognized adverse effect of duloxetine 4, 2, occurring in clinical trials as one of the most common side effects, though it tends to be mild to moderate and transient 4.

Critical Safety Consideration with Fatty Liver

The grade 2 fatty liver is relevant but not a contraindication to either medication. Duloxetine does not require routine aminotransferase monitoring according to guidelines 1, though there was one case report of pregabalin-induced hepatotoxicity 5. However, the fatty liver itself does not necessitate stopping either medication unless liver enzymes are significantly elevated.

Stepwise Management Algorithm

Step 1: Reduce Pregabalin Dose Immediately

• Decrease pregabalin by 25-50% of the current dose 1, 6
• If the patient is on 150 mg twice daily (300 mg/day), reduce to 75 mg twice daily or 100 mg twice daily
• Use "asymmetric dosing" with the larger dose at bedtime to minimize daytime dizziness 6
• Do not abruptly discontinue as this can worsen symptoms

Step 2: Maintain Duloxetine at Current Dose

• Continue duloxetine without dose adjustment initially 7, 4
• The decreased appetite from duloxetine is typically transient and resolves within weeks 4
• Duloxetine's nausea and appetite effects can be minimized by ensuring the patient took 30 mg once daily for one week before increasing to 60 mg 1

Step 3: Monitor and Reassess in 3-7 Days

• Assess if dizziness improves with reduced pregabalin dose
• Check orthostatic vital signs to rule out orthostatic hypotension
• Evaluate fall risk, especially given the patient's age
• Monitor appetite and weight

Step 4: Further Dose Adjustments Based on Response

If dizziness persists after pregabalin reduction:

• Consider switching from combination therapy to duloxetine monotherapy 7, 8
• Duloxetine 60 mg daily is effective as monotherapy for neuropathic pain 7, 4
• Recent meta-analysis shows duloxetine and pregabalin have similar efficacy, with duloxetine having a better safety profile regarding dizziness 8, 9

If dizziness resolves but pain control is inadequate:

• Slowly re-titrate pregabalin upward using a "low and slow" approach 6
• Increase by 25-50 mg every 3-7 days as tolerated 1
• Maximum benefit may require 4 weeks at the optimal dose 1

If decreased appetite persists or worsens:

• This is less urgent than dizziness but monitor weight loss
• Consider reducing duloxetine to 30 mg daily if appetite loss is severe
• The appetite suppression typically resolves within 2-4 weeks 4

Important Clinical Pitfalls to Avoid

Do Not Assume Both Medications Are Equally Responsible

Pregabalin is the more likely cause of dizziness in this age group 3, 10. A retrospective study found that age ≥65 years is an independent risk factor for somnolence and dizziness with pregabalin (adjusted OR: 2.507) 10.

Do Not Discontinue Both Medications Simultaneously

This would leave the patient without pain control and potentially cause withdrawal symptoms. Guidelines recommend switching to an alternative first-line medication if one fails, not stopping all treatment 1.

Do Not Overlook Renal Function

Both medications require dose adjustment in renal impairment 1, 3. Pregabalin is eliminated primarily by renal excretion, and elderly patients often have reduced creatinine clearance even with normal serum creatinine. Check renal function and adjust doses accordingly.

Do Not Ignore the Combination Burden

While guidelines support combination therapy for partial responders 1, this patient is experiencing intolerable side effects from the combination. Recent evidence suggests that a fixed-dose combination of LOW-dose pregabalin (75 mg twice daily) plus LOW-dose duloxetine (30 mg twice daily) achieves similar pain relief to high-dose pregabalin (150 mg twice daily) with comparable side effects 11. However, monotherapy with duloxetine may be the safest option given her age and symptoms 8, 9.

When to Consider Alternative Approaches

If symptoms persist despite dose optimization:

• Switch to duloxetine monotherapy at 60 mg daily 7, 8
• Consider topical lidocaine for localized neuropathic pain 1
• Refer to pain specialist if first-line monotherapy and combination therapy both fail 1

The fatty liver does not change this management approach unless transaminases are elevated >3 times upper limit of normal, in which case hepatology consultation is warranted 12.